Cencora

• 1. Introduction

  ›

  Cencora handles roughly 20 percent of all pharmaceuticals sold and distributed across the United States. That is not a footnote. That is a fact about a single company, and it shapes the medicine that reaches hospitals, retail pharmacies, nursing homes, and cancer clinics from coast to coast. The company known today as Cencora was trading under a different name for more than two decades: AmerisourceBergen. Before that, it was two separate firms whose merger in 2001 quietly created one of the most consequential supply chains in American healthcare. How did a pharmaceutical wholesaler grow into an entity handling tens of billions of dollars in annual revenue while simultaneously becoming a defendant in lawsuits filed by states, counties, and the federal government? And what does it mean that the company most Americans have never heard of touches nearly every prescription they fill? Those are the questions worth sitting with.

• 2. The 2001 Merger

  ›

  AmeriSource Health Corporation and Bergen Brunswig Corporation came together in 2001 to form AmerisourceBergen. David Yost, who had been CEO of AmeriSource before the deal, stayed on to lead the combined company. The merger was not just a financial transaction; it produced an infrastructure of considerable scale. The combined entity would come to operate 26 pharmaceutical distribution centers in the United States and nine more in Canada. Four specialty distribution centers were added on top of that. Packaging production capacity reached over one million square feet, spread across facilities in the US and the UK. By 2012, AmerisourceBergen ranked as the largest company by revenue based in Pennsylvania. The acquisition of World Courier, described in company materials as the largest specialty courier company in the world, added more than 150 company-owned offices globally. That global footprint was not just logistical bragging; it made AmerisourceBergen a node in the international movement of biopharmaceuticals. Steven Collis replaced Yost as CEO in July 2011, a transition that would coincide with a decade of aggressive acquisition.

• 3. Building by Acquisition

  ›

  In 2011, the company acquired IntrinsiQ for $35 million and picked up Premier Source for an undisclosed sum. The pace of deal-making continued the following year, when AmerisourceBergen agreed in March 2012 to buy World Courier Group Inc, a transportation and logistics provider for the biopharmaceutical industry, for $520 million. January 2015 brought the $2.5 billion purchase of MWI Veterinary, a move that extended the company's reach beyond human medicine. Later that same year, in October, they agreed to buy PharMEDium, a compounding drug company, for $2.58 billion. On the 3rd of January 2018, the company acquired H. D. Smith, which held the distinction of being the largest privately held national pharmaceutical wholesaler in the United States. The largest single deal came on the 2nd of June 2021, when AmerisourceBergen acquired Alliance Healthcare from Walgreens Boots Alliance for approximately $6.5 billion; the purchase was structured as $6.275 billion in cash plus two million shares of AmerisourceBergen common stock. That acquisition carried a backstory: in March 2016, Walgreens Boots Alliance had exercised an option to purchase 22.7 million shares of AmerisourceBergen stock, which gave it a 15 percent stake in the company, setting up the eventual deal five years later. The acquisition spree continued into the next chapter of the company's life: on the 2nd of January 2025, Cencora acquired 85 percent of Retina Consultants of America for approximately $4.4 billion.

• 4. Good Neighbor Pharmacy

  ›

  Good Neighbor Pharmacy is a retailers' cooperative network of more than 3,400 independently owned and operated pharmacies across the United States. AmerisourceBergen sponsors the network and owns the name. The arrangement lets small, independent pharmacy owners operate under a recognizable banner while drawing on the supply chain muscle of one of the country's largest drug distributors. The network also runs ThoughtSpot, an annual trade show held in both Orlando and Las Vegas, which functions as a gathering point for independent pharmacists operating within the cooperative's orbit.

• 5. Remdesivir and the Pandemic

  ›

  In June 2020, the U.S. Department of Health and Human Services made an unusual public announcement. HHS had struck an agreement with Gilead, the manufacturer of remdesivir, which was then the first coronavirus drug authorized for use in American hospitals. Under the deal, HHS agreed to Gilead's wholesale acquisition price. In exchange, during the period through the end of September 2020, American patients would receive more than 90 percent of Gilead's projected output of over 500,000 treatment courses of the drug. AmerisourceBergen was named as the company that would work alongside HHS and state governments to allocate shipments of remdesivir vials to hospitals across the country. The arrangement gave a single drug wholesaler a central role in distributing what was at that moment the most urgently sought therapeutic in American medicine.

• 6. The Opioid Lawsuits

  ›

  West Virginia was among the first states to sue AmerisourceBergen, alleging that the company shipped inordinate amounts of pain medication into the state, contributing to the opioid epidemic. In December 2019, Michigan became the first state to sue AmerisourceBergen and three other opioid distributors as drug dealers, filing under the Michigan Drug Dealer Liability Act. Oklahoma Attorney General Mike Hunter filed suit in May 2020 in Bryan County District Court, alongside parallel lawsuits against Cardinal Health and McKesson. Those three suits alleged that the companies together had provided enough opioids to Bryan County that every adult resident could have received 144 hydrocodone tablets. AmerisourceBergen was among four companies that agreed to pay $260 million to two Ohio counties before a broader resolution took shape. In January 2022, AmerisourceBergen, McKesson, Cardinal Health, and Johnson & Johnson reached a $26 billion settlement covering all but five of the states that had sued them. The deal encompassed 46 states, Washington DC, and roughly 90 percent of municipal governments that were party to the litigation. Estimates suggested the companies could have faced up to $95 billion in penalties had the cases gone to trial. None of the four companies admitted wrongdoing. In 2022, the United States Department of Justice filed its own federal lawsuit, with prosecutors in New Jersey, Colorado, Pennsylvania, and New York alleging that the company had distributed opioids that were later resold illegally.

• 7. The Syringe Fraud Settlement

  ›

  In October 2018, AmerisourceBergen agreed to pay $625 million to settle civil fraud allegations. The allegations covered repackaging and selling adulterated drugs, distributing unapproved new drugs, double billing, and providing kickbacks to physicians. A prior misdemeanor conviction related to pre-filled syringes lacking FDA approval added another $260 million to the tally, bringing the total to $885 million. The civil settlement required AmerisourceBergen to admit specific facts. Between January 2001 and January 2014, two subsidiaries, MII and OSC, ran what the company called the PFS Program. At MII, an ABC subsidiary in Alabama, workers removed drug product from glass vials, pooled multiple vials in untested plastic containers, and then filled syringes from those pooled contents. By harvesting the overfill in each vial, the company extracted more doses than it had paid for. The leftover unopened vials were then sold to other customers, and to the company's own subsidiary ABDC for resale. At peak operation, MII manufactured thousands of syringes daily, eventually reaching over one million per year. Those syringes were distributed throughout the United States. Approximately 57 percent of the patients injected with these syringes were beneficiaries of federal healthcare programs. The annual profit from the PFS Program ranged between $2.3 and $14.4 million, with total profits reaching at least $99.6 million across the 13 years the program ran. The entire PFS Program was deliberately excluded from the company's standard regulatory audit and compliance checks.

• 8. A New Name

  ›

  On the 30th of August 2023, the company completed its transition from AmerisourceBergen to Cencora and began trading on the New York Stock Exchange under the ticker symbol COR. The rebrand did not change the underlying business; the company remained one of the world's largest pharmaceutical distributors with the same four operating units: AmerisourceBergen Drug Corporation, AmerisourceBergen Specialty Group, AmerisourceBergen Consulting Services, and World Courier. In May 2024, Cencora disclosed that it had been the subject of a cyber incident in which patient information was exposed. The fiscal year 2019 figures give a sense of the financial scale behind the new name: annual revenue of $179.58 billion and earnings of $1.11 billion. In September of that year, shares had traded above $88 and the company's market capitalization exceeded $19.2 billion. The Retina Consultants of America acquisition in January 2025 suggests the company's appetite for expanding beyond traditional drug distribution has not slowed under its new identity.